The Biotech Growth Trust PLC (BIOG)
Category Sector Equity Biotechnology
This investment trust can be held in an Investment ISA, SIPP and Investment Account
Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show Ongoing charges as 0% please review the investment literature for details on the charges that will apply. The Financial Conduct Authority will review this in 2025.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
Sell
873.00p
Buy
879.00p
-10.70p (-1.21%)
Discount/Premium
-9.56%
Estimated NAV
977.442p
Prices updated at 03 Jan 2025, 14:02 GMT
| Prices minimum 15 mins delay
Prices in GBX
Investment objective
The Company seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Shares & trades
- Dividends
- Portfolio
- Risk
- News & dates
- Trust info
- Director info
Company name
Frostrow Capital LLP
Legal structure
Closed Ended Investment Company
Domicile
United Kingdom
Fiscal year end
31 Mar 2025
Launch date
23 Jun 1997
Lead manager
Geoffrey Hsu
Lead manager start date
19 May 2005
Lead fund manager biography
Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation.
Head office
25 Southampton Buildings
London
United Kingdom
WC2A 1AL